Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Evaluation of the 755nm Alexandrite Laser for the Treatment of Tattoos

This study has been completed.
Information provided by (Responsible Party):
Cynosure, Inc. Identifier:
First received: December 18, 2012
Last updated: February 7, 2014
Last verified: February 2014
The purpose of this study is to collect further data on the safety and efficacy of removing unwanted non cosmetic tattoos (including recalcitrant) using the 755nm Alexandrite laser.

Condition Intervention
Device: 755nm Alexandrite Laser
Device: 755nm Alexandrite Laser with CAP Array

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluation of the 755nm Alexandrite Laser for the Treatment of Tattoos

Further study details as provided by Cynosure, Inc.:

Primary Outcome Measures:
  • Photographic Evaluation [ Time Frame: up to 3 months post last treatment ]
    2D photography comparing pre and post treatment results

Enrollment: 20
Study Start Date: December 2011
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 755nm Alexandrite Laser
755nm Alexandrite Laser
Device: 755nm Alexandrite Laser
755nm Alexandrite Laser
Experimental: 755nm Alexandrite Laser with CAP Array
755nm Alexandrite Laser with CAP Array
Device: 755nm Alexandrite Laser with CAP Array
755nm Alexandrite Laser with CAP Array


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Is a healthy male or female between 18 and 85 years old.
  2. Has unwanted non-cosmetic tattoo(s) and wishes to undergo laser treatments to remove them.
  3. Is willing to consent to participate in the study.
  4. Is willing to comply with all requirements of the study including being photographed, following post treatment care and attending all treatment and follow up visits

Exclusion Criteria:

  1. Is hypersensitive to light exposure.
  2. Has active localized or systemic infection.
  3. Is taking medication(s) for which sunlight is a contraindication.
  4. Has a history of squamous cell carcinoma or melanoma.
  5. Has a history of keloid scarring.
  6. Has used oral isotretinoin (Accutane®) within 12 months of initial treatment or plans on using during the course of the study. Note: Skin must regain its normal degree of moisture prior to treatment.
  7. Has a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications.
  8. Is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period.
  9. Is allergic to lidocaine, tetracaine or Xylocaine with epinephrine.
  10. Has any other reason determined by the physician to be ineligible to participate in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01754207

United States, Massachusetts
Skin Care Physicians
Chestnut Hill, Massachusetts, United States, 02467
Sponsors and Collaborators
Cynosure, Inc.
Study Director: Patricia Krantz Cynosure, Inc.
  More Information

Responsible Party: Cynosure, Inc. Identifier: NCT01754207     History of Changes
Other Study ID Numbers: CYN11-PICO-D-A-TAT
Study First Received: December 18, 2012
Last Updated: February 7, 2014 processed this record on April 28, 2017